- Strategy
- Payers
- AI
- Cybersecurity
- Device Development
- Studies/Published Research
- Ethics
- Regulatory
- Digital Biomarkers
- Data Science
- Companion Diagnostics
- Clinical Care
- Digital Therapeutics
- Academic Research
- Virtual Reality
- RWE
- Digital Endpoints
- Medical Devices (Class II and Class III)
- Commercialization
- Clinical Trials
- Drug-Device Combinations
- SaMD
- Remote Patient Monitoring
- Patient Engagement
- Profiles/Q&A
Body Vision Medical Announces Distribution Agreements to Provide Greater Access to LungVision AI Imaging System.
The imaging company signed deals with Prism Technologies Limited, Paragon Care, and Kral Medical Solutions.
Body Vision Medical announced that it will be bringing its AI-powered imaging system LungVision to new markets, including Hong Kong, Macao, the Greater Bay Area, Australia, New Zealand, and Romania. To facilitate these new markets, the company announced partnerships with Prism Technologies Limited, Paragon Care, and Kral Medical Solutions.
LungVision allows HCPs to take images obtained by a C-arm device and create a full intraoperative CT scans.
In a press release, Body Vision Medical CEO David Webster said, “We view these partnerships as a pivotal stride towards democratizing Body Vision's LungVision™ and giving lung patients worldwide access to the latest in AI-powered imaging technology. In many parts of the world with high lung cancer incidence, limited access to advanced medical solutions has translated into lower patient survival rates. With innovative yet cost-effective solutions like LungVision, we hope to challenge and change that status quo."
What Pharma Fears Most About AI
October 4th 2023In this Q&A with Pharmaceutical Executive®, Andrew Hopkins, founder and CEO of Exscientia, reveals how artificial intelligence (AI) is currently being utilized in the pharma industry, predictions for where AI can be implemented in the future, and what pharma fears most about AI.
